<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04580355</url>
  </required_header>
  <id_info>
    <org_study_id>23626219.7.0000.5418</org_study_id>
    <nct_id>NCT04580355</nct_id>
  </id_info>
  <brief_title>Impact of Non-surgical Periodontal Therapy on Oral and Gut Microbiome</brief_title>
  <official_title>Impact of Non-surgical Periodontal Therapy With or Without Antibiotics on Oral and Gut Microbiome in Patients With Stage III/IV and Grade C Periodontitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Periodontitis is an inflammatory disease characterized by a dysbiotic microbiome which can&#xD;
      lead to bone destruction and tooth loss. Several studies had been reported the association to&#xD;
      periodontal disease with systemic conditions and this relation suggests and axis that links&#xD;
      oral and gut microbiome. In order to clarify the impact of periodontal condition on gut&#xD;
      microbiome, we aim to evaluate the clinical, immunological parameters and the microbiological&#xD;
      condition by sequencing of subgingival biofilm and stool samples both before and after&#xD;
      non-surgical periodontal treatment with and without antibiotics as adjunct.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the oral-gut axis microbiome at 3 months</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Concentration of bacteria in the subgingival biofilm and stool samples</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of biofilm gene expression on oral microbiome at 3 months</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>RNA-seq of 3 samples FMUD+AM group and validation by quantitative polymerase chain reaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the baseline inflammatory markers levels in gingival crevicular fluid (pg/uL) and stool samples</measure>
    <time_frame>Baseline and 90 days</time_frame>
    <description>Concentration of cytokines and biomarkers in gingival crevicular fluid and in stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the baseline relative clinical attachment level at 3 months</measure>
    <time_frame>Baseline, 30 days and 90 days</time_frame>
    <description>Distance from the bottom of the pocket to the stent margin.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Microbial Colonization</condition>
  <condition>Periodontal Diseases</condition>
  <condition>Periodontal Inflammation</condition>
  <arm_group>
    <arm_group_label>FMUD + Placebos</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus placebo administration prescribed on the day of treatment, every 8 hours for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FMUD + AM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One session of full-mouth ultrasonic debridement (FMUD) with a time limit of 45 minutes plus 500 mg Amoxicillin and 250 mg Metronidazole (AM) prescribed on the day of treatment, every 8 hours for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>One-Stage Full Mouth Debridement</intervention_name>
    <description>Periodontal debridement</description>
    <arm_group_label>FMUD + AM</arm_group_label>
    <arm_group_label>FMUD + Placebos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin 500mg</intervention_name>
    <description>Administration of Amoxicillin 500mg prescribed on the day of treatment tid for 7 days.</description>
    <arm_group_label>FMUD + AM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole 400mg</intervention_name>
    <description>Administration of Metronidazole 400mg prescribed on the day of treatment tid for 7 days.</description>
    <arm_group_label>FMUD + AM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Placebo</intervention_name>
    <description>Administration of Placebo on the day of treatment tid for 7 days.</description>
    <arm_group_label>FMUD + Placebos</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metronidazole Placebo</intervention_name>
    <description>Administration of Placebo on the day of treatment tid for 7 days.</description>
    <arm_group_label>FMUD + Placebos</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of Stage III/IV and grade C Periodontitis&#xD;
&#xD;
          -  Presence of at least 20 teeth&#xD;
&#xD;
          -  Good general health&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating&#xD;
&#xD;
          -  Were suffering from any other systemic diseases (e.g., cardiovascular, diabetes)&#xD;
&#xD;
          -  Received antimicrobials in the previous 6 months&#xD;
&#xD;
          -  Received a course of periodontal treatment within the last 6 months&#xD;
&#xD;
          -  Were taking long-term anti-inflammatory drugs&#xD;
&#xD;
          -  Smoking habits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Campinas, UNICAMP</name>
      <address>
        <city>Piracicaba</city>
        <state>Sao Paulo</state>
        <zip>13414-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renato CV Casarin, Prof. Dr.</last_name>
      <phone>+55192106-5394</phone>
      <email>casarinrcv@yahoo.com.br</email>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>May 25, 2021</last_update_submitted>
  <last_update_submitted_qc>May 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Renato Casarin</investigator_full_name>
    <investigator_title>Professor of Periodontics in Piracicaba Dental School-FOP/UNICAMP</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Periodontal Diseases</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Metronidazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

